FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
The FDA found safety problems with weight-loss medicines made by smaller companies and is blocking some imports. This matters because it shows regulators are watching closely—companies selling these medicines need to prove they're safe and made properly, or they could face trouble.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.